Murine models provide insight to the development of non-alcoholic fatty liver disease

Nutrition Research Reviews

Volumn 28, Issue 2, 2015, Pages 133-142

  Reid, D T ^a   Eksteen, B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Animal models; Non alcoholic fatty liver; Non alcoholic steatohepatitis; Obesity

Indexed keywords

CHOLINE; LEPTIN; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; METHIONINE;

ARTICLE; CARBOHYDRATE INTAKE; CELL STRESS; CHOLESTEROL DIET; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DISEASE PREDISPOSITION; DISORDERS OF LIPID METABOLISM; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN RESISTANCE; LEPTIN DEFICIENCY; LIPID DIET; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER MITOCHONDRION; METABOLIC SYNDROME X; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL DEFICIENCY; OBESITY; PATHOGENESIS; PROTEIN DEPLETION; RISK FACTOR;

EID: 84949625893     PISSN: 09544224     EISSN: 14752700     Source Type: Journal    
DOI: 10.1017/S0954422415000128     Document Type: Article

References (98)

1. Caballero B (2007) The global epidemic of obesity: an overview. Epidemiol Rev 29, 1-5.
2. Rezaianzadeh A, Namayandeh SM & Sadr SM (2012) National Cholesterol Education Program Adult Treatment Panel III versus International Diabetic Federation Definition of metabolic syndrome, which one is associated with diabetes mellitus and coronary artery disease? Int J Prev Med 3, 552-558.
3. Boyle JP, Thompson TJ, Gregg EW, et al. (2010) Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 8, 29.
4. Hamaguchi M, Takeda N, Kojima T, et al. (2012) Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol 18, 1508-1516.
5. Levene AP & Goldin RD (2012) The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61, 141-152.
6. Michelotti GA, Machado MV & Diehl AM (2013) NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10, 656-665.
7. Bellentani S & Tiribelli C (2001) The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 35, 531-537.
8. Yasui K, Hashimoto E, Komorizono Y, et al. (2011) Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9, 428-433, e50.
9. Engl J, Sturm W, Sandhofer A, et al. (2008) Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur J Clin Invest 38, 238-244.
10. Milic S & Stimac D (2012) Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 30, 158-162.
11. Pacana T & Fuchs M (2012) The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. Clin Liver Dis 16, 599-613.
12. Bugianesi E, Moscatiello S, Ciaravella MF, et al. (2010) Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 16, 1941-1951.
13. Tilg H & Moschen AR (2008) Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19, 371-379.
14. Larrain S & Rinella ME (2012) A myriad of pathways to NASH. Clin Liver Dis 16, 525-548.
15. Buchman AL (2009) The addition of choline to parenteral nutrition. Gastroenterology 137, Suppl. 5, S119-S128.
16. Petta S, Vanni E, Bugianesi E, et al. (2015) PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Aliment Pharmacol Ther 41, 939-948.
17. Richmond TK, Thurston I, Sonneville K, et al. (2015) Racial/ethnic differences in accuracy of body mass index reporting in a diverse cohort of young adults. Int J Obes (Lond) 39, 546-548.
18. Nigam P, Misra A & Colles SL (2013) Comparison of DEXA-derived body fat measurement to two race-specific bioelectrical impedance equations in healthy Indians. Diabetes Metab Syndr 7, 72-77.
19. Jitnarin N, Poston WS, Haddock CK, et al. (2014) Accuracy of body mass index-defined obesity status in US firefighters. Saf Health Work 5, 161-164.
20. Machado MV, Michelotti GA, Xie G, et al. (2015) Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLOS ONE 10, e0127991.
21. Ludwig J, Viggiano TR, McGill DB, et al. (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55, 434-438.
22. Kong M, Zhu L, Bai L, et al. (2014) Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model. Am J Physiol Gastrointest Liver Physiol 307, G883-G893.
23. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 1343-1351.
24. Lottenberg AM, Afonso Mda S, Lavrador MS, et al. (2012) The role of dietary fatty acids in the pathology of metabolic syndrome. J Nutr Biochem 23, 1027-1040.
25. Das SK & Balakrishnan V (2011) Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease. Indian J Clin Biochem 26, 202-209.
26. Handa P, Maliken BD, Nelson JE, et al. (2014) Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology 60, 133-145.
27. Kim KH, Jeong YT, Oh H, et al. (2013) Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 19, 83-92.
28. Kwanten WJ, Martinet W, Michielsen PP, et al. (2014) Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue. World J Gastroenterol 20, 7325-7338.
29. Tuyama AC & Chang CY (2012) Non-alcoholic fatty liver disease. J Diabetes 4, 266-280.
30. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. (2010) Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52, 913-924.
31. Kanuri G, Landmann M, Priebs J, et al. (2015) Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice. Eur J Nutr (epublication ahead of print version 24 May 2015).
32. Wieckowska A & Feldstein AE (2008) Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 28, 386-395.
33. Day CP & James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114, 842-845.
34. Musso G, Gambino R & Cassader M (2013) Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 52, 175-191.
35. Volynets V, Kuper MA, Strahl S, et al. (2012) Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 57, 1932-1941.
36. Day CP & James OF (1998) Hepatic steatosis: innocent bystander or guilty party? Hepatology 27, 1463-1466.
37. Rahimi RS & Landaverde C (2013) Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract 28, 40-51.
38. Farrell GC, van Rooyen D, Gan L, et al. (2012) NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 6, 149-171.
39. Pagadala MR & McCullough AJ (2012) The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis 16, 487-504.
40. Waller-Evans H, Hue C, Fearnside J, et al. (2013) Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome. PLOS ONE 8, e82825.
41. Montgomery MK, Hallahan NL, Brown SH, et al. (2013) Mouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding. Diabetologia 56, 1129-1139.
42. Nagao M, Asai A, Inaba W, et al. (2014) Characterization of pancreatic islets in two selectively bred mouse lines with different susceptibilities to high-fat diet-induced glucose intolerance. PLOS ONE 9, e84725.
43. Sims EK, Hatanaka M, Morris DL, et al. (2013) Divergent compensatory responses to high-fat diet between C57BL6/J and C57BLKS/J inbred mouse strains. Am J Physiol Endocrinol Metab 305, E1495-E1511.
44. Heiker JT, Kunath A, Kosacka J, et al. (2014) Identification of genetic loci associated with different responses to high-fat diet-induced obesity in C57BL/6N and C57BL/6J substrains. Physiol Genomics 46, 377-384.
45. Podrini C, Cambridge EL, Lelliott CJ, et al. (2013) High-fat feeding rapidly induces obesity and lipid derangements in C57BL/6N mice. Mamm Genome 24, 240-251.
46. Nagarajan P, Mahesh Kumar MJ, Venkatesan R, et al. (2012) Genetically modified mouse models for the study of nonalcoholic fatty liver disease. World J Gastroenterol 18, 1141-1153.
47. d Oliveira RB, Carvalho CP, Polo CC, et al. (2014) Impaired compensatory β-cell function and growth in response to high-fat diet in LDL receptor knockout mice. Int J Exp Pathol 95, 296-308.
48. Bojic LA, Burke AC, Chhoker SS, et al. (2014) Peroxisome proliferator-activated receptor γ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 34, 52-60.
49. Depner CM, Traber MG, Bobe G, et al. (2013) A metabolomic analysis of omega-3 fatty acid-mediated attenuation of Western diet-induced nonalcoholic steatohepatitis in LDLR-/-mice. PLOS ONE 8, e83756.
50. Subramanian S, Goodspeed L, Wang S, et al. (2011) Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res 52, 1626-1635.
51. Trak-Smayra V, Paradis V, Massart J, et al. (2011) Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int J Exp Pathol 92, 413-421.
52. Tamura Y, Sugimoto M, Murayama T, et al. (2008) Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 28, 2195-2201.
53. Arsov T, Silva DG, O'Bryan MK, et al. (2006) Fat aussie - a new Alstr�m syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. Mol Endocrinol 20, 1610-1622.
54. Larter CZ, Yeh MM, Haigh WG, et al. (2013) Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease. Obesity (Silver Spring) 21, 1189-1199.
55. Van Rooyen DM, Larter CZ, Haigh WG, et al. (2011) Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141, 1393-1403, 1403.e1-1403.e5.
56. Carpenter KC, Strohacker K & McFarlin BK (2013) Considerations to maximize fat mass gain in a mouse model of diet-induced weight gain. Lab Anim 47, 266-273.
57. Omar B, Pacini G & Ahr�n B (2012) Differential development of glucose intolerance and pancreatic islet adaptation in multiple diet induced obesity models. Nutrients 4, 1367-1381.
58. Pyndt Jorgensen B, Hansen JT, Krych L, et al. (2014) A possible link between food and mood: dietary impact on gut microbiota and behavior in BALB/c mice. PLOS ONE 9, e103398.
59. Brainard RE, Watson LJ, Demartino AM, et al. (2013) High fat feeding in mice is insufficient to induce cardiac dysfunction and does not exacerbate heart failure. PLOS ONE 8, e83174.
60. Xu L, Kim JK, Bai Q, et al. (2013) 5-Cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol Pharmacol 83, 648-658.
61. Corbin JA, Bhaskar V, Goldfine ID, et al. (2014) Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity. PLOS ONE 9, e88684.
62. Carpene C, Gomez-Zorita S, Gupta R, et al. (2014) Combination of low dose of the anti-adipogenic agents resveratrol and phenelzine in drinking water is not sufficient to prevent obesity in very-high-fat diet-fed mice. Eur J Nutr 53, 1625-1635.
63. Clemmensen C, Smajilovic S, Madsen AN, et al. (2013) Increased susceptibility to diet-induced obesity in GPRC6A receptor knockout mice. J Endocrinol 217, 151-160.
64. Noyan-Ashraf MH, Shikatani EA, Schuiki I, et al. (2013) A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127, 74-85.
65. Galloway CA, Lee H, Brookes PS, et al. (2014) Decreasing mitochondrial fission alleviates hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 307, G632-G641.
66. Lafarge JC, Pini M, Pelloux V, et al. (2014) Cathepsin S inhibition lowers blood glucose levels in mice. Diabetologia 57, 1674-1683.
67. Hennig EE, Mikula M, Goryca K, et al. (2014) Extracellular matrix and cytochrome P450 gene expression can distinguish steatohepatitis from steatosis in mice. J Cell Mol Med 18, 1762-1772.
68. Brown ML, Yukata K, Farnsworth CW, et al. (2014) Delayed fracture healing and increased callus adiposity in a C57BL/6J murine model of obesity-associated type 2 diabetes mellitus. PLOS ONE 9, e99656.
69. Ouyang S, Hsuchou H, Kastin AJ, et al. (2014) Diet-induced obesity suppresses expression of many proteins at the blood-brain barrier. J Cereb Blood Flow Metab 34, 43-51.
70. Weitman ES, Aschen SZ, Farias-Eisner G, et al. (2013) Obesity impairs lymphatic fluid transport and dendritic cell migration to lymph nodes. PLOS ONE 8, e70703.
71. Yang Y, Smith DL Jr, Keating KD, et al. (2014) Variations in body weight, food intake, and body composition after long-term high-fat diet feeding in C57BL/6J mice. Obesity (Silver Spring) 22, 2147-2155.
72. Tetri LH, Basaranoglu M, Brunt EM, et al. (2008) Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295, G987-G995.
73. Yang ZH, Miyahara H, Takeo J, et al. (2012) Diet high in fat and sucrose induces rapid onset of obesity-related metabolic syndrome partly through rapid response of genes involved in lipogenesis, insulin signalling and inflammation in mice. Diabetol Metab Syndr 4, 32.
74. Tan JT, McLennan SV, Williams PF, et al. (2013) Connective tissue growth factor/CCN-2 is upregulated in epididymal and subcutaneous fat depots in a dietary-induced obesity model. Am J Physiol Endocrinol Metab 304, E1291-E1302.
75. Spruss A, Henkel J, Kanuri G, et al. (2012) Female mice are more susceptible to nonalcoholic fatty liver disease: sexspecific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. Mol Med 18, 1346-1355.
76. Hodgson K, Govan B, Ketheesan N, et al. (2013) Dietary composition of carbohydrates contributes to the development of experimental type 2 diabetes. Endocrine 43, 447-451.
77. Ritze Y, Bardos G, Hubert A, et al. (2014) Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice. Br J Nutr 112, 1-7.
78. Perez-Martinez L, Perez-Matute P, Aguilera-Lizarraga J, et al. (2014) Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of nonalcoholic fatty liver disease (NAFLD). J Antimicrob Chemother 69, 1903-1910.
79. Oliveira MC, Menezes-Garcia Z, Henriques MC, et al. (2013) Acute and sustained inflammation and metabolic dysfunction induced by high refined carbohydrate-containing diet in mice. Obesity (Silver Spring) 21, E396-E406.
80. Heinrichs D, Berres ML, Coeuru M, et al. (2014) Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis. FASEB J 28, 5136-5147.
81. Weltman MD, Farrell GC & Liddle C (1996) Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111, 1645-1653.
82. Bellafante E, Murzilli S, Salvatore L, et al. (2013) Hepaticspecific activation of peroxisome proliferator-activated receptor γ coactivator-1β protects against steatohepatitis. Hepatology 57, 1343-1356.
83. Buchman AL, Ament ME, Sohel M, et al. (2001) Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. J Parenter Enteral Nutr 25, 260-268.
84. Coulon S, Legry V, Heindryckx F, et al. (2013) Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 57, 1793-1805.
85. Matsumoto M, Hada N, Sakamaki Y, et al. (2013) An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol 94, 93-103.
86. Sahai A, Malladi P, Pan X, et al. (2004) Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287, G1035-G1043.
87. Rinella ME, Elias MS, Smolak RR, et al. (2008) Mechanisms of hepatic steatosis in mice fed a lipogenic methionine cholinedeficient diet. J Lipid Res 49, 1068-1076.
88. Salamone F, Galvano F, Marino Gammazza A, et al. (2012) Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Dig Liver Dis 44, 334-342.
89. Charlton M, Krishnan A, Viker K, et al. (2011) Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301, G825-G834.
90. Fujii H, Enomoto M, Fukushima W, et al. (2009) Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol 44, 608-614.
91. Matsuzawa N, Takamura T, Kurita S, et al. (2007) Lipidinduced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46, 1392-1403.
92. Savard C, Tartaglione EV, Kuver R, et al. (2013) Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 57, 81-92.
93. Hirsova P, Ibrahim SH, Bronk SF, et al. (2013) Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLOS ONE 8, e70599.
94. Streba LA, Vere CC, Rogoveanu I, et al. (2015) Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 21, 4103-4110.
95. Torres DM & Harrison SA (2012) Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 32, 30-38.
96. Alexander J, Torbenson M, Wu TT, et al. (2013) Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in noncirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol 28, 848-854.
97. Fujii H & Kawada N (2012) Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol 47, 215-225.
98. Kawada N, Imanaka K, Kawaguchi T, et al. (2009) Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 44, 1190-1194.